Core Insights - Emergent BioSolutions Inc. has secured new purchase orders valued at $29 million from an international government partner for a multi-product supply agreement, reflecting the increasing priority on defense and preparedness by governments [1][2] - The company will receive approximately $26 million in 2025, in addition to over $100 million in sales generated year to date for its medical countermeasures (MCM) portfolio outside of the U.S. [1] Company Overview - Emergent specializes in developing, manufacturing, and supplying medical countermeasures for national security and public health preparedness, addressing threats such as smallpox, anthrax, and botulism [2][4] - The company emphasizes the importance of maintaining stockpiles of products based on population needs, available products, and government resources [2] Industry Context - There is a growing trend among NATO members to increase defense expenditures from two percent to five percent of GDP, which supports the international expansion of Emergent's MCM business [3]